Curis, Inc. Announces Investigator-Initiated Phase II Study Results Presented at 102nd American Association for Cancer Research Annual Meeting 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome (BCNS), which is also commonly referred to as Gorlin syndrome. This data was presented at the 102nd Annual Meeting of the American Association for Cancer Research being held in Orlando, Florida, April 2-6, 2011.